Loading
An ovarian cancer study that captured tumour vesicles from blood by surface proteins, including TROP2, and then read RNA inside them.
Three ovarian cancer vesicle surface markers (FRalpha, MSLN and TROP2) were used; the integrated score had an area under the curve of 0.99 in training and 0.93 (95% CI 0.88 to 0.97) in validation, and 0.93 for stage I and II.
Capturing tumour vesicles by a surface marker before reading their RNA is feasible; it was tested for detection, not residual disease.
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/